Article

Coverage of atypical antipsychotics among medicare drug plans in the state of washington for fiscal year 2007.

Department of Pharmaceutical Sciences, Division of Pharmaceutical Outcomes and Policy, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
The Primary Care Companion to The Journal of Clinical Psychiatry 02/2008; 10(4):313-7. DOI: 10.4088/PCC.v10n0407
Source: PubMed

ABSTRACT To examine drug coverage and patient costs for 6 atypical antipsychotics (olanzapine, quetiapine, ziprasidone, aripiprazole, clozapine, and risperidone) in Medicare Part D formularies using health plan data from the state of Washington.
Fiscal year 2007 coverage and cost-sharing characteristics for 57 prescription drug plans (PDPs) and 43 Medicare advantage prescription drug plans (MAPDs) were collected from the Centers for Medicare and Medicaid Services. Plans were compared in terms of formulary restrictions, out-of-pocket costs, and premium charges. Medicare released plan information for fiscal year 2007 in October 2006. Data were collected for this study in February 2007.
Almost all plans covered the 6 atypical antipsychotics. The PDPs were more likely to restrict coverage than the MAPDs. Prior authorization requirements were enforced in 5% to 21% of plans, depending on plan type and medication. Monthly drug plan premiums were higher for PDPs than MAPDs, but the MAPDs had concurrent monthly health premiums. About 80% of MAPDs and 60% of PDPs also had no annual deductible for medications. The patient out-of-pocket cost for atypical antipsychotics varied depending on the stage of coverage-median monthly drug costs ranged from $5 to $50 during the initial period, but if costs exceeded the annual cap, patients were responsible for the full cost of the drug, which ranged from $292 to $665. Patients with low incomes and those who exceeded the annual spending limit ($3850 in fiscal year 2007) had a median monthly cost of $17 to $33.
There is considerable variation across health plans in terms of patients' out-of-pocket drug costs. Given the significant needs and vulnerabilities of Medicare beneficiaries with mental illness, changes for atypical antipsychotic coverage should be monitored carefully, and the complexity of Medicare drug plans should be minimized.

0 Followers
 · 
86 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pharmacotherapeutic treatments for drug addiction offer new options, but only if they are affordable for patients. The objective of this study is to assess the current availability and cost of five common antiaddiction medications in the largest federal medication insurance program in the US, Medicare Part D. In early 2010, we collected coverage and cost data from 41 Medicare Part D prescription drug plans (PDPs) and 45 Medicare Advantage Plans (MAPs) in Washington State. The great majority of Medicare plans (82-100%) covered common pharmacotherapeutic treatments for drug addiction. These Medicare plans typically placed patent protected medications on their highest formulary tiers, leading to relatively high patient co-payments during the initial Part D coverage period. For example, median monthly co-payments for buprenorphine (Suboxone®) were about $46 for PDPs, and about $56 for MAPs. While Medicare prescription plans usually cover pharmacotherapeutic treatments for drug addiction, high co-payments can limit access. For example, beneficiaries without supplemental coverage who use Vivitrol® would exceed their initial coverage cap in 7-8 months, reaching the "doughnut hole" in their Part D coverage and becoming responsible for the full cost of the medication (over $900 per month). The 2010 Patient Protection and Affordable Care Act will gradually eliminate this coverage gap, and loss of patent protection for other antiaddiction medications (Suboxone® and Campral®) should also drive down patient costs, improving access and compliance.
    Drug and alcohol dependence 12/2010; 114(2-3):201-6. DOI:10.1016/j.drugalcdep.2010.08.016 · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Object: To give an overview of the current literature on the cost-effectiveness of antipsychotics used in the treatment of schizophrenia. Method: We conducted a relevant literature search and contacted authors who had published literature in the field of pharmacoeconomics. Results: Much of the evidence in pharmacoeconomic studies is contradictory, and results may be determined by study methodology and the scope of outcome evaluations. More studies are needed to draw firm conclusions about the cost-effectiveness of various individual antipsychotics. However, with respect to clozapine, there is evidence that it is cost-effective in treatment-resistant patients after at least one year, especially if high users of inpatient facilities. Conclusions: Calculating the cost-effectiveness of a treatment is complex, and should incorporate real world parameters such as the value of good clinical outcome, tolerability and quality of life against the direct and indirect costs of schizophrenia to the individual and society as a whole. The variety of methodological issues employed in pharmacoeconomic studies is a limiting factor in seeking to synthesise the evidence, and comparisons between different agents in this field will undoubtedly continue to be a matter of debate, with further studies being required. Declaration of interest: Ruth I Ohlsen has received honoraria and consultancy fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Novartis and Sanofi-Aventis. David Taylor has received research support from Janssen-Cilag, Bristol-Myers Squibb and Sanofi-Aventis; and has served as a consultant to Novartis, AstraZeneca, Eli Lilly, Bristol-Myers Squibb and Janssen-Cilag. He has also received speaking honoraria from all of these companies. Dr Kopal Tandon has no interests to declare. Dr Katherine J Aitchison has been an invited member of Advisory Boards for Johnson & Johnson, Lundbeck, Roche Diagnostics, and Bristol-Myers Squibb, and has received consultancy fees from Bristol-Myers Squibb Pharmaceuticals Limited, Roche Diagnostics, Johnson & Johnson Pharmaceutical Research and Development, and Lundbeck. She is also on the UK Core Steering Group for Abilify (aripiprazole). However, none of the above played any role in the drafting or review of this paper.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine changes in the cost and coverage of atypical antipsychotics among Medicare prescription drug plans and Medicare advantage plans in the state of Washington. Coverage and cost data were obtained in February 2007 and 2008 from the Medicare Prescription Drug Plan Finder, an online database administered by the Centers for Medicare and Medicaid Services. Premiums, deductibles, out-of-pocket costs, and coverage limits were compared for prescription drug plans (PDPs) and for Medicare advantage plans (MAPs). The number of PDPs in the state of Washington fell slightly from 57 in 2007 to 53 in 2008, while the number of MAPs rose from 43 in 2007 to 52 in 2008. In 2008, the mean monthly drug premium increased by 15% among PDPs and by 20% among MAPs. Mean copayments for the majority of atypical antipsychotics increased from 2007 to 2008. More plans added quantity limits for atypical antipsychotics, but use of other pharmacy management tools varied by type of plan and antipsychotic. PDP and MAP participants in the state of Washington paid more for atypical antipsychotics in 2008 than they did in 2007. Affordability of atypical antipsychotics continues to be a concern, particularly for beneficiaries who are not eligible for Medicaid or the low-income subsidy.
    The Primary Care Companion to The Journal of Clinical Psychiatry 12/2009; 11(6):316-21. DOI:10.4088/PCC.08m00737

Full-text (2 Sources)

Download
35 Downloads
Available from
May 30, 2014